DDInter1562 DDInter1789
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. However, it has a negligible effect on altering the development and progression of breast cancer itself.[label] The most common causes of osteoporosis
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
Raloxifene {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Thalidomide
Raloxifene {u} (Compound) downregulates {v} (Gene) CCND3
CCND3 {u} (Gene) is upregulated by {v} (Compound) Thalidomide
Raloxifene {u} (Compound) upregulates {v} (Gene) SMARCD2
SMARCD2 {u} (Gene) is upregulated by {v} (Compound) Thalidomide
Raloxifene {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Thalidomide
Raloxifene {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Thalidomide
Raloxifene {u} (Compound) resembles {v} (Compound) Flavoxate
Flavoxate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Raloxifene {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Menadione
Menadione {u} (Compound) resembles {v} (Compound) Thalidomide
Raloxifene {u} (Compound) downregulates {v} (Gene) CCND3
CCND3 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Thalidomide
Raloxifene {u} (Compound) upregulates {v} (Gene) SMARCD2
SMARCD2 {u} (Gene) regulates {v} (Gene) FGFR2
FGFR2 {u} (Gene) is bound by {v} (Compound) Thalidomide
Raloxifene {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Menadione
Menadione {u} (Compound) resembles {v} (Compound) Thalidomide
Raloxifene (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Thalidomide (Compound)
Raloxifene (Compound) downregulates CCND3 (Gene) and CCND3 (Gene) is upregulated by Thalidomide (Compound)
Raloxifene (Compound) upregulates SMARCD2 (Gene) and SMARCD2 (Gene) is upregulated by Thalidomide (Compound)
Raloxifene (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Thalidomide (Compound)
Raloxifene (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Raloxifene (Compound) resembles Flavoxate (Compound) and Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Raloxifene (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Menadione (Compound) and Menadione (Compound) resembles Thalidomide (Compound)
Raloxifene (Compound) downregulates CCND3 (Gene) and CCND3 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Thalidomide (Compound)
Raloxifene (Compound) upregulates SMARCD2 (Gene) and SMARCD2 (Gene) regulates FGFR2 (Gene) and FGFR2 (Gene) is bound by Thalidomide (Compound)
Raloxifene (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Menadione (Compound) and Menadione (Compound) resembles Thalidomide (Compound)